Prelude Therapeutics Incorporated is a precision oncology company focused on discovering and developing novel cancer therapies for patients with high unmet medical needs. The company leverages expertise in cancer biology, medicinal chemistry, and clinical development to create targeted treatments, including small-molecule inhibitors, protein degraders, and precision antibody-drug conjugates. Operating in the biopharmaceutical industry, Prelude Therapeutics prioritizes mechanisms with strong biological rationale, aiming to address cancers driven by well-characterized mutations or pathways where existing treatments are limited or ineffective.

The company generates revenue primarily through strategic partnerships, upfront payments, milestone payments, and potential royalties from licensed programs. Its collaborations, such as the exclusive option agreement with Incyte Corporation for the JAK2V617F inhibitor program and the multi-program partnership with AbCellera Biologics, provide near-term capital and long-term financial upside. Prelude Therapeutics does not currently commercialize its own products but anticipates future revenue from licensing, regulatory milestones, and eventual product sales if its candidates receive approval.

The company operates through the following segments:

• JAK2V617F Program: This segment focuses on developing mutant-selective JAK2 inhibitors for myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis. The lead candidate, PRT12396, received IND clearance in early 2026 and is advancing under an exclusive option agreement with Incyte, which could yield up to $910 million in total payments if exercised.

• KAT6A Selective Degrader Program: This segment targets KAT6A, a histone acetyltransferase implicated in estrogen receptor-positive breast cancer and other solid tumors. The company’s selective degrader approach aims to improve safety and efficacy over non-selective inhibitors, with an IND filing planned for mid-2026.

• Precision Antibody Drug Conjugates (ADCs): This segment develops ADCs using proprietary degrader payloads, combining Prelude’s small-molecule expertise with partners like AbCellera. The collaboration includes early-stage programs targeting tumor-specific antigens, with potential for improved therapeutic index and reduced toxicity compared to traditional cytotoxic payloads.

• Discovery Programs: This segment encompasses preclinical initiatives, including mutated calreticulin degrader-antibody conjugates for myelofibrosis and essential thrombocythemia, as well as SMARCA2/4 and CDK9 degraders. These programs aim to address niche oncology indications with limited treatment options.

Prelude Therapeutics competes in the precision oncology space, where it faces established pharmaceutical companies and specialized biotechs with greater resources and advanced pipelines. Key competitors for its JAK2V617F program include Incyte, Ajax Therapeutics, and Cogent Biosciences, while its KAT6A degrader program contends with Pfizer, Olema Oncology, and Ideaya Biosciences. The company differentiates itself through its drug discovery engine, which integrates cancer biology and medicinal chemistry to rapidly identify and optimize clinical candidates. Its focus on targeted protein degradation and precision ADCs also positions it at the forefront of emerging therapeutic modalities, offering potential advantages in efficacy and safety over conventional treatments.

The company’s customer base consists of patients with underserved cancers, including those with myeloproliferative neoplasms, estrogen receptor-positive breast cancer, and other solid or hematological malignancies. Its therapies are designed for use in clinical settings, with eventual commercialization targeting hospitals, oncology clinics, and healthcare providers. Prelude Therapeutics also collaborates with pharmaceutical partners, such as Incyte and AbCellera, which may play a role in future commercialization efforts.